NASDAQ: CTMX · Biotechnology
Over the past week, CytomX Therapeutics (CTMX) pulled in 14 mentions across Reddit, X and news, and the read is an Adanos Sell. The crowd averages 25% bullish but is deeply split: News runs 75% bullish while X sits at just 0%. Wall Street is more constructive, with 8 of 8 analysts rating CTMX a buy.
There is little buzz around CTMX this week and little agreement on direction, which is why it reads as a Sell.
Wall Street’s 100% buy share sits next to a crowd that ranges from X at 0% to News at 75%. No other tracker puts the two side by side.
Across 8 analysts the consensus is a Strong Buy: 8 buy calls against 0 sell, with an average 12-month price target of $12.25.
The Adanos signal blends each source’s bullish ratio, source breadth, buzz intensity and 3-day momentum. This week bullish sits just below the neutral line, momentum is cooling and the 3 sources disagree sharply, so the read is a Sell.
Analysts sit 75 points above the crowd average of 25%, the professionals are more constructive than retail. The split is inside the crowd: News reads 75% bullish while X sits at 0%, a 75-point spread that single-source trackers miss.
Weekly price context: this Alpha Vantage chart keeps its own dated range; the sentiment metrics elsewhere on this page may be newer. Over the 30-day window, CytomX Therapeutics (CTMX) buzz held subdued around 33.2 while the price drifted down 15.9% across the period. The chart tracks how social and news attention moved against end-of-day price. Average daily trading volume across the displayed trading days is 4.4M shares. Updated Sep 26, 2026. Over the last 7 trading days, CTMX lost 4.3%. Buzz activity in the recent week averaged 31.1 and was variable, swinging between 18.6 and 48.5. Recent volume is in line with the 30-day average, reflecting steady institutional and retail participation. Daily crowd sentiment leaned bullish on 8 of the 16 days with directional mentions, shown as the green, grey and red breakdown bars below the chart.
Signal metrics use the latest 7 days; contributor and breadth context uses the 30-day chart window.
No Polymarket data for this stock this week.
Query sentiment for CTMX and 2110+ stocks from your terminal. Filter by source, timeframe and signal strength.
View CLIEmbed live CTMX sentiment on your own site with drop-in web components.
View WidgetsThis week’s sentiment from Adanos, with fundamentals and analyst consensus. A quick-reference snapshot for Sep 27, 2026.
| Adanos signal | Sell |
|---|---|
| Analyst consensus | Strong Buy (8 / 0 / 0) |
| Crowd bullish (7d) | 25% |
| Avg price target | $12.25 |
| Most bullish source | News, 75% |
| Most bearish source | X, 0% |
| Sentiment spread | 75 pts |
| Mentions (7d) | 14 |
| Market cap | $599.2M |
| P/E · Forward P/E | n/a · 14.2 |
| EPS · Beta | -$0.56 · 2.1 |
| Revenue (TTM) | $18.3M · 0% margin |
| Industry | Biotechnology |
Based on aggregated sentiment from Reddit, X and News sources, CytomX Therapeutics (CTMX) currently carries an Adanos sell signal with 93/100 conviction. The current cross-source average reads 25% bullish across 3 active sources. Those sources contribute 14 tracked mentions over the last 7 days. This is a sentiment-based reading, not financial advice.
Reddit discussion around CytomX Therapeutics (CTMX) is fairly quiet with 0 mentions over the last 7 days; the 30-day context spans 1 tracked subreddits. The 7-day tone is 0% bullish; 3-day activity momentum is stable, suggesting steady attention.
The crowd reads bearish on CytomX Therapeutics (CTMX), averaging 25% bullish across 3 tracked sources over the last 7 days. The two ends of the range are News at 75% bullish and X at 0%, a 75-point spread. On the professional side, 8 of 8 analysts rate CTMX a buy.
Of the 8 analysts covering CytomX Therapeutics (CTMX), 8 rate it a buy, 0 a hold and 0 a sell, for a strong buy consensus. The average price target is $12.25. That puts the street ahead of the crowd, which averages 25% bullish.
CytomX Therapeutics (CTMX)'s cross-source average is bearish at 25% bullish. Source readings are split: 1 source leans bullish and 2 sources lean bearish. X reads 0% bullish, News reads 75% bullish and reddit coverage is the most negative at 0% bullish. The combined signal points to broad sell-side pressure with 93/100 conviction.
The cross-source average is bearish for CytomX Therapeutics (CTMX) at 25% bullish. Source readings are split: 1 source leans bullish and 2 sources lean bearish. The most bearish reading is reddit at 0% bullish. 3-day activity momentum is falling across X. The sell signal carries 93/100 conviction.
X is the dominant discussion channel with 10 mentions (71% of total volume). News contributes 4 mentions. The cross-source average is bearish at 25% bullish. Source readings are split: 1 source leans bullish and 2 sources lean bearish.
The Adanos signal blends bullish ratio, buzz score, source breadth and 3-day activity momentum into a single buy/sell reading. CTMX's sell signal at 93/100 conviction reflects a bearish cross-source average at 25% bullish. Source readings are split: 1 source leans bullish and 2 sources lean bearish. It is a research shortcut, not financial advice.
The CTMX sentiment page is regenerated from the latest 7-day tracking window at each build. Data reflects the most recent Reddit posts, tweets and news articles available in the current publishing cycle.
Peers are ranked first by matching the Sell signal, then by the closest bullish ratio. Discussion activity breaks any remaining ties.
Every data point on this page comes from the Adanos sentiment APIs. Get a free API key and start querying Reddit, X, News and Polymarket sentiment programmatically.
Get Free API Key